中国临床药理学与治疗学2024，Vol.29Issue(5)：482-487,6.DOI:10.12092/j.issn.1009-2501.2024.05.001
非肽类促性腺激素释放激素拮抗剂在子宫肌瘤治疗中的应用研究进展
Progress in the application of non-peptide gonadotropin-releasing hormone antagonist in the treatment of uterine fibroid
摘要
Abstract
Non-peptide gonadotropin-releasing hormone antagonist(GnRH-antagonist)is a highly efficient and selective antagonist of GnRH receptor.The oral preparations(Elagolix,Relugolix and Linza-golix)had been approved for listing abroad.It shows efficacy in reducing the size of uterine fi-broid and controlling heavy bleeding.Appropriate combination of'add-back'therapy could improve the safety in medical application and patient com-pliance.Compared with other hormonal pharma-ceuticals,oral GnRH-antagonists showed promising prospects in the treatment of uterine fibroid.关键词
促性腺激素释放激素拮抗剂/子宫肌瘤/治疗/有效性/安全性Key words
gonadotropin releasing hormone an-tagonists/uterine fibroid/treatment/effectiveness/safety分类
医药卫生引用本文复制引用
郑韵熹,易晓芳,徐丛剑..非肽类促性腺激素释放激素拮抗剂在子宫肌瘤治疗中的应用研究进展[J].中国临床药理学与治疗学,2024,29(5):482-487,6.基金项目
国家重点研发计划"生育健康及妇女儿童健康保障"重点专项(2022YFC2704000) （2022YFC2704000）
